Zimbabwe has declined a major American health deal worth 367 million US dollars (272 million pounds) over five years because of Washington's request for confidential information.
This move was revealed after a official document dated December was disclosed, indicating that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesman later explained that the United States was requesting genetic material for research and profit but was not willing to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged further negotiations to secure a deal suitable to all parties so the nation's critical HIV treatment initiative can continue.
Broader Context
Zimbabwe's decision follows a similar case in Kenya, where a court suspended a related health funding agreement after legal challenges were raised about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its expenditure was "wasteful" and his government was seeking direct bilateral agreements to enhance openness and accountability.
According to reports, 16 African countries have so far signed similar health pacts, constituting more than $18.3bn in new funding.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information for a long time, with no equivalent assurance of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that provided information," his statement read.
"Put simply, our country would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be available to our people should a new health crisis emerge."
Sovereignty and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending systems already established via the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to deal with future global health emergencies.
"This system is intended to guarantee that when a country contributes its information, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the resources to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to continued dialogue with our US partners on how subsequent collaboration could be designed in a way that respects the sovereignty and interests of both nations."
Medical Community Response
Medical experts said it recognised the government's concerns, but suggested that talks must proceed considering much of the country's HIV programmes were funded by external financing.
"Where technical issues arise, such as those relating to information security or implementation frameworks, these can often be resolved through detailed discussion and mutually agreed protections," it commented.
The halted deal emphasises the continuing debate between receiving vital international aid and protecting a country's data in an increasingly interconnected world.